Dr. Goldschmidt joined CASI Pharmaceuticals in April 2016 as Senior Vice President of Business Development. Dr. Goldschmidt brings more than 25 years of commercial and business development experience in the biotechnology and pharmaceutical sectors. Before joining CASI, Dr. Goldschmidt held senior positions at several public and private biopharmaceutical companies, most recently as Chief Operating Officer at Macrophage Therapeutics. Prior, he was Vice President of Business Development at ImmuneXcite, an immuno-oncology biotech based in Lexington, MA. From 2007 to 2013, Dr. Goldschmidt was Vice President of Business and Commercial Development at TetraLogic Pharmaceuticals, where he lead business development and supported the company’s Initial Public Offering (IPO). Earlier in his career, Dr. Goldschmidt held several roles of increasing responsibility at Johnson & Johnson, Wyeth Pharmaceuticals, and SmithKline Beecham. Dr. Goldschmidt has had direct leadership responsibility for the development, pre-launch, launch and brand marketing of numerous oncology and specialty products over the course of his career, including the products Velcade®, Yondelis®, Mylotarg®, Torisel®, Hycamtin®, and Doxil®. Dr. Goldschmidt is a graduate of Villanova University and went on to receive a master’s degree from Drexel University and a Ph.D. from Temple University School of Medicine.